- Home
- SPRY vs INVA Comparison
SPRY vs INVA Comparison
Compare SPRY & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- INVA
- Stock Information
- Founded
- SPRY 2015
- INVA 1996
- Country
- SPRY United States
- INVA United States
- Employees
- SPRY N/A
- INVA N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- SPRY Health Care
- INVA Health Care
- Exchange
- SPRY Nasdaq
- INVA Nasdaq
- Market Cap
- SPRY 1.1B
- INVA 1.2B
- IPO Year
- SPRY N/A
- INVA 2004
- Fundamental
- Price
- SPRY $14.08
- INVA $18.70
- Analyst Decision
- SPRY Strong Buy
- INVA Buy
- Analyst Count
- SPRY 4
- INVA 1
- Target Price
- SPRY $26.00
- INVA N/A
- AVG Volume (30 Days)
- SPRY 1.4M
- INVA 574.0K
- Earning Date
- SPRY 03-20-2025
- INVA 02-27-2025
- Dividend Yield
- SPRY N/A
- INVA N/A
- EPS Growth
- SPRY N/A
- INVA 46.55
- EPS
- SPRY N/A
- INVA 0.99
- Revenue
- SPRY $2,568,000.00
- INVA $352,745,000.00
- Revenue This Year
- SPRY $66,750.00
- INVA $16.20
- Revenue Next Year
- SPRY $508.63
- INVA N/A
- P/E Ratio
- SPRY N/A
- INVA $18.84
- Revenue Growth
- SPRY 8460.00
- INVA 21.46
- 52 Week Low
- SPRY $6.13
- INVA $14.33
- 52 Week High
- SPRY $18.51
- INVA $21.28
- Technical
- Relative Strength Index (RSI)
- SPRY 71.29
- INVA 63.20
- Support Level
- SPRY $11.00
- INVA $18.19
- Resistance Level
- SPRY $12.48
- INVA $18.89
- Average True Range (ATR)
- SPRY 0.85
- INVA 0.30
- MACD
- SPRY 0.42
- INVA 0.18
- Stochastic Oscillator
- SPRY 95.43
- INVA 89.89
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.